Journal News

JBC: Researchers clock DNA’s recovery time

Jonathan Griffin
November 01, 2019

In the time it takes for an Amazon Prime delivery to arrive, cells damaged by chemotherapy can fix their most important DNA almost completely. That’s true in mouse livers mice at least, according to a new study.

Circadian rhythmicity of metabolic processesCircadian rhythmicity of metabolic processes has a significant impact on physiology and behavior. National Human Genome Research Institute

Researchers found that DNA damaged by the chemotherapy drug cisplatin is mostly good as new in noncancerous tissue within two circadian cycles, or two days. The results, published in the Journal of Biological Chemistry, could inform strategies for administering chemotherapy at times that maximize tumor damage while minimizing side effects.

Side effects of cisplatin include kidney, liver and peripheral nerve injury. Cisplatin kills cells, cancerous or not, by damaging their DNA, so Nobel laureate Aziz Sancar and his team aimed to uncover the pattern of DNA repair in healthy cells. In normal cells, the circadian clock drives the rhythm of DNA repair, but not in tumors.

“Most cancers do not have a functional clock and so, basically any time that it’s good for the normal tissue, you can hit the cancer,” said Sancar, a professor at the University of North Carolina School of Medicine.

In an earlier study, Sancar’s team looked at DNA repair across a mouse genome, uncovering two mechanisms of circadian-controlled DNA repair.

They found that for some genes, transcription — during which damaged DNA is recognized and patched up — was controlled by the circadian clock. The pattern was specific to each gene, with repair peaking at different times of day. For the remaining DNA that is not transcribed or expressed, repair was less efficient but also clock-controlled, and maximum repair occurred between 4 p.m. and 6 p.m., Sancar said.

In this previous experiment, they examined DNA two hours after injecting cisplatin, but in their new work in JBC, Sancar’s team wanted to study recovery on a more clinically relevant time scale.

Patients get cisplatin intravenously at weekly, 10-day or two week intervals, allowing recovery time between doses, Sancar explained. “And so we wanted to know what happens over those long periods.”

Using a technique developed in their lab, the team captured and sequenced fragments of damaged DNA from mice injected with cisplatin. Over 70 days, they produced maps displaying where and when DNA was fixed at the resolution of a single nucleotide.

The DNA of transcribed genes was just about fully mended in two circadian cycles, Sancar said. Most repair in the first 48 hours was to these genes.

The remaining damage in nontranscribed DNA is not harmful in normal cells that aren’t replicating, Sancar said. But for cancer cells, which divide uncontrollably, this damage could lead to cell death.

Before this information is considered in the clinic, further experiments are needed, Sancar said.

Sancar is working with oncologists, evaluating new cisplatin regimens in mice implanted with human tumors to find a treatment that reduces toxicity in normal tissue while hitting cancer hard.

Jonathan Griffin

Jonathan Griffin is a science communicator for all ASBMB journals. Follow him on Twitter.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

Rodents in space Keeping bone and muscle strong on the ISS
News

Rodents in space Keeping bone and muscle strong on the ISS

September 19, 2020

Researchers helped mice stay mighty with an experiment to counter the effects of microgravity. The gene treatment might also enhance muscle and bone health on Earth — and in humans.

Understanding the impact of Type 1 diabetes susceptibility genes
Research Spotlight

Understanding the impact of Type 1 diabetes susceptibility genes

September 17, 2020

Starting in eighth grade, a series of mentors who saw something special in Sharifa Love–Rutledge helped her stay on the path to being a researcher — and becoming a mentor to others.

Re-creating coagulation in a lab
Journal News

Re-creating coagulation in a lab

September 15, 2020

Threatened arthropods are in the crossfire of medical and conservation efforts, but new research could benefit horseshoe crabs and humans alike.

Decoy receptor neutralizes coronavirus in cell cultures
News

Decoy receptor neutralizes coronavirus in cell cultures

September 13, 2020

To keep COVID-19 from infecting tissues once they’re exposed, a new study led by Erik Procko suggests luring the virus with an engineered, free-floating receptor protein that binds the virus and blocks infection.

When plants and their microbes are not in sync, the results can be disastrous
News

When plants and their microbes are not in sync, the results can be disastrous

September 06, 2020

Sheng-Yang He’s lab has discovered that plants can develop dysbiosis, a condition similar to inflammatory bowel disease in humans, with severe consequences.

A zest for synthetic biology
Feature

A zest for synthetic biology

September 02, 2020

Metabolic engineers seek to overcome the challenges of mass-producing commodity chemicals, such as limonene, an oil from orange peels.